Figure 1.
Incidence of ≥Gr3 AEs, overall and across trials. (A) Flow diagram of median and IQR of all ≥Gr3 overall and separated based on the trial, as well as ≥Gr3 NC AEs based on outcomes. ∗One patient was not evaluable for response owing to early death. (B) Pie graph of all ≥Gr3 AEs based on the system. (C) Pie graph of ≥Gr3 NC AEs based on the system. (D) Pie graph of highest ≥Gr3 NC AEs per patient per secondary analysis that excluded duplicate and overlapping terms. (E,F) Dot plot of the number of ≥Gr3 AEs (and ≥Gr3 NC AEs) per patient based on the trial, with horizontal line representing the median per patient. Pair-wise rank comparisons using Mann-Whitney are represented as P values at the top of graphs, with Kruskal-Wallis comparisons across all 3 trials to the right. GI, gastrointestinal.

Incidence of ≥Gr3 AEs, overall and across trials. (A) Flow diagram of median and IQR of all ≥Gr3 overall and separated based on the trial, as well as ≥Gr3 NC AEs based on outcomes. ∗One patient was not evaluable for response owing to early death. (B) Pie graph of all ≥Gr3 AEs based on the system. (C) Pie graph of ≥Gr3 NC AEs based on the system. (D) Pie graph of highest ≥Gr3 NC AEs per patient per secondary analysis that excluded duplicate and overlapping terms. (E,F) Dot plot of the number of ≥Gr3 AEs (and ≥Gr3 NC AEs) per patient based on the trial, with horizontal line representing the median per patient. Pair-wise rank comparisons using Mann-Whitney are represented as P values at the top of graphs, with Kruskal-Wallis comparisons across all 3 trials to the right. GI, gastrointestinal.

Close Modal

or Create an Account

Close Modal
Close Modal